The DOI matches its Crossref record; 58 of the 58 references it cites were found in a registry or an index.
LATE to the PART-y
Open accessAbstract
Sir, We wish to address the recent proposal of a disease entity newly titled ‘limbic-predominant age-related TDP-43 encephalopathy (LATE)’ (Nelson et al., 2019) which, to our reading, is itself a derivative of the 2016 proposed term cerebral age-related TDP-43 with sclerosis (CART) (Nelson et al., 2016). The transactive response DNA binding protein of ∼43 kD (TDP-43) was first reported in 2006 to be a main component of ubiquitinated inclusions in autopsy-confirmed cases of frontotemporal lobar degeneration (FTLD) negative for tau immunoreactivity (Arai et al., 2006; Neumann et al., 2006). Over a decade of research into FTLD-TDP (and FTLD-U before it) has highlighted important phenotypic variability in TDP-43-immunoreactive lesions resulting in the identification of five different types of FTLD-TDP (Mackenzie et al., 2006, 2011; Sampathu et al., 2006; Josephs et al., 2009; Lee et al., 2011, 2017). There have also been important advances in the molecular and biochemical characterization of TDP-immunoreactive in FTLD-TDP (Sampathu et al., 2006; Hasegawa et al., 2008; Igaz et al., 2008; Zhang et al., 2009; Bigio et al., 2013; Laferriere et al., 2019). Soon after the initial characterization of TDP-immunoreactive lesions in FTLD and amyotrophic lateral sclerosis, TDP-immunoreactive lesions were identified in 25–33% of cases with pathologically confirmed Alzheimer’s disease (Amador-Ortiz et al., 2007; Higashi et al., 2007). TDP-immunoreactive lesions related to Alzheimer’s disease were initially thought to appear first in the hippocampus (Amador-Ortiz et al., 2007), but more detailed morphological studies involving multiple anatomical regions revealed the amygdala to be the earliest affected region (Higashi et al., 2007; Hu et al., 2008; Arai et al., 2009) followed by the entorhinal cortex and hippocampus, occipitotemporal cortex, insular and inferior temporal cortex, brainstem, and frontal neocortex and basal ganglia (Josephs et al., 2014, 2016); a scheme that has been independently validated (Tan et al., 2015). TDP-immunoreactive lesions have also been described in cognitively normal individuals (Wilson et al., 2011; Arnold et al., 2013; Uchino et al., 2015; Wennberg et al., 2019) including those with asymptomatic definite primary age related tauopathy (PART) (Josephs et al., 2017; Zhang et al., 2019), as well being associated with other well-defined clinic-pathological entities (Fig. 1) including Lewy body disease (with or without co-existing Alzheimer’s disease) (Arai et al., 2009; McAleese et al., 2017), the amyotrophic lateral sclerosis/parkinsonism-dementia complex of Guam (Hasegawa et al., 2007; Geser et al., 2008), Pick’s disease (Freeman et al., 2008), progressive supranuclear palsy (Yokota et al., 2010; Koga et al., 2017), corticobasal degeneration (Uryu et al., 2008; Koga et al., 2018), polyglutamine diseases such as Huntington’s disease (Schwab et al., 2008), Machado-Joseph disease (Tan et al., 2009) and spinocerebellar ataxia type 2 (Toyoshima et al., 2011), Perry syndrome (Wider et al., 2009), and chronic traumatic encephalopathy (McKee et al., 2010). TDP-43 immunoreactive inclusions can be found in many different neurodegenerative diseases. Currently TDP-43 proteinopathies are divided into primary TDP-43 proteinopathies and mixed (secondary) TDP-43 proteinopathies. AD = Alzheimer’s disease; ALS = amyotrophic lateral sclerosis; CBD = corticobasal degeneration; CTE = chronic traumatic encephalopathy; FTLD = frontotemporal lobar degeneration; LBD = Lewy body disease; PART = primary age related tauopathy; PDC = Parkinson-dementia complex; PSP = progressive supranuclear palsy; SCA = spinocerebellar ataxia. The term LATE is proposed as a catchy acronym to describe the presence of TDP-immunoreactive lesions in Alzheimer’s disease, as well as in older adults. The review manuscript describing LATE, of which many of the authors of this response are cited in, provides a thorough appraisal of an important topic and is meritorious in promoting recognition of TDP-43 and encouraging future research, as well as the development of neuroimaging and molecular biomarkers. However, we question the term’s novelty and nosology, the framework that seemingly separates LATE from FTLD-TDP and other diseases, and the proposed guidelines provided for assessing LATE and LATE-NC. As the authors identify, the term LATE is new, although there is an extensive literature on the relationship between TDP-immunoreactive inclusions and clinical and imaging features, both in isolation and in association with Alzheimer’s disease. LATE is used to rebrand already characterized features, yet identifies no new TDP-43 pathological subtype, no link between TDP-immunoreactive pathology with new cognitive symptoms (other than likelihood of dementia diagnosis) according to known brain–behaviour relationship, and no biochemical demonstration that TDP-immunoreactive lesions in older adults with and without Alzheimer’s disease are equivalent to each
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Neuropathological stageing of Alzheimer-related changes.
Braak, H., & Braak, E. (1991) · Acta Neuropathologica · doi:10.1007/bf00308809 · Cited by 16,123
Ubiquitinated TDP-43 in Frontotemporal Lobar Degeneration and Amyotrophic Lateral Sclerosis
Neumann, M., Sampathu, D. M., Kwong, L. K., Truax, A. C., Micsenyi, M. C., Chou, T. T., Bruce, J., Schuck, T., Grossman, M., Clark, C. M., et al. (2006) · Science · doi:10.1126/science.1134108 · Cited by 6,576
Self-citationMirra, S. S., Heyman, A., McKeel, D., Sumi, S. M., Crain, B. J., Brownlee, L. M., Vogel, F. S., Hughes, J. P., Belle, G. V., Berg, L., et al. (1991) · Neurology · doi:10.1212/wnl.41.4.479 · Cited by 4,961
Phases of Aβ-deposition in the human brain and its relevance for the development of AD
Thal, D. R., Rüb, U., Orantes, M., & Braak, H. (2002) · Neurology · doi:10.1212/wnl.58.12.1791 · Cited by 3,490
Arai, T., Hasegawa, M., Akiyama, H., Ikeda, K., Nonaka, T., Mori, H., Mann, D., Tsuchiya, K., Yoshida, M., Hashizume, Y., et al. (2006) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2006.10.093 · Cited by 2,732
Self-citationLimbic-predominant age-related TDP-43 encephalopathy (LATE): consensus working group report
Nelson, P. T., Dickson, D. W., Trojanowski, J. Q., Jack, C. R., Boyle, P. A., Arfanakis, K., Rademakers, R., Alafuzoff, I., Attems, J., Brayne, C., et al. (2019) · Brain · doi:10.1093/brain/awz099 · Cited by 1,547
Primary age-related tauopathy (PART): a common pathology associated with human aging
Crary, J. F., Trojanowski, J. Q., Schneider, J. A., Abisambra, J. F., Abner, E. L., Alafuzoff, I., Arnold, S. E., Attems, J., Beach, T. G., Bigio, E. H., et al. (2014) · Acta Neuropathologica · doi:10.1007/s00401-014-1349-0 · Cited by 1,467
Self-citationA harmonized classification system for FTLD-TDP pathology
Mackenzie, I. R. A., Neumann, M., Baborie, A., Sampathu, D. M., Du Plessis, D., Jaros, E., Perry, R. H., Trojanowski, J. Q., Mann, D. M. A., & Lee, V. M. Y. (2011) · Acta Neuropathologica · doi:10.1007/s00401-011-0845-8 · Cited by 1,017
Self-citationTDP‐43 immunoreactivity in hippocampal sclerosis and Alzheimer's disease
Amador‐Ortiz, C., Lin, W., Ahmed, Z., Personett, D., Davies, P., Duara, R., Graff‐Radford, N. R., Hutton, M. L., & Dickson, D. W. (2007) · Annals of Neurology · doi:10.1002/ana.21154 · Cited by 916 · cited 1×
“In fact, it has been demonstrated that there are different subtypes of TDP immunoreactivity that have different regional associations, with only one specific subtype of neurofibrillary tangle-associated TDP proving to be truly limbic-predominant (Amador-Ortiz et al., 2007; Josephs et al., 2019; Zhang et al., 2019).”
Phosphorylated TDP‐43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis
Hasegawa, M., Arai, T., Nonaka, T., Kametani, F., Yoshida, M., Hashizume, Y., Beach, T. G., Buratti, E., Baralle, F., Morita, M., et al. (2008) · Annals of Neurology · doi:10.1002/ana.21425 · Cited by 777
Self-citation
Cited by
TDP-43 Pathology in Alzheimer’s Disease
Meneses, A., Koga, S., O’Leary, J., Dickson, D. W., Bu, G., & Zhao, N. (2021) · Molecular Neurodegeneration · doi:10.1186/s13024-021-00503-x · Cited by 363
Boeve, B. F., Boxer, A. L., Kumfor, F., Pijnenburg, Y., & Rohrer, J. D. (2022) · The Lancet Neurology · doi:10.1016/s1474-4422(21)00341-0 · Cited by 218
Concurrent tau pathologies in frontotemporal lobar degeneration with TDP‐43 pathology
Koga, S., Zhou, X., Murakami, A., Fernandez De Castro, C., Baker, M. C., Rademakers, R., & Dickson, D. W. (2022) · Neuropathology and Applied Neurobiology · doi:10.1111/nan.12778 · Cited by 30
Metadata
- Authors
- Josephs, K. A., Mackenzie, I., Frosch, M. P., Bigio, E. H., Neumann, M., Arai, T., Dugger, B. N., Ghetti, B., Grossman, M., Hasegawa, M., Herrup, K., Holton, J., Jellinger, K., Lashley, T., McAleese, K. E., Parisi, J. E., Revesz, T., Saito, Y., Vonsattel, J. P., Whitwell, J. L., Wisniewski, T., & Hu, W.
- Affiliations
- Mayo Clinic (US)
- University of British Columbia (CA)
- Harvard University (US)
- Northwestern University (US)
- German Center for Neurodegenerative Diseases (DE)
- University of Tsukuba (JP)
- University of California Davis Medical Center (US)
- Indiana University (US)
- University of Pennsylvania (US)
- Tokyo Metropolitan Institute of Medical Science (JP)
- University of Pittsburgh (US)
- UCL Queen Square Institute of Neurology (GB)
- Medical University of Vienna (AT)
- Newcastle University (GB)
- UCL Queen Square Institute of Neurology, University College London, London, UK
- National Center of Neurology and Psychiatry (JP)
- Columbia University (US)
- Alzheimer’s Disease Center Research, New York University, NY, USA
- Emory University (US)
- Corresponding author
- Josephs, Keith A
- ORCID
- Venue
- Brain
- Publisher
- Oxford University Press (OUP)
- Published
- 2019-07-29
- Volume
- 142
- Issue
- 9
- Pages
- e47-e47
- ISSN
- 0006-8950 (ISSN-L)
- 1460-2156
- PMC
- PMC6736234
- OpenAlex
- W2966040091
- Cited by
- 66
- References
- 58
- Citations by year
- 2026: 2 · 2025: 5 · 2024: 8 · 2023: 9 · 2022: 11 · 2021: 12 · 2020: 12 · 2019: 7
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Brain (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- DZNE Pub (submittedVersion, other-oa)
- Funders
- National Institute on Aging (P01AG017586, P30AG008051, P30AG013854, P30AG062421)
- National Institute of Neurological Disorders and Stroke (R01NS073502)
- Topics
- Health Sciences › Medicine › Clinical Neurology › Amyotrophic Lateral Sclerosis Research
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Keywords
- Lates, TDP-43, limbic-predominant age-related TDP-43 encephalopathy, Alzheimer's disease, amygdala, frontotemporal lobar degeneration, TDP-43 pathology, disease nomenclature
- MeSH terms
- DNA-Binding Proteins, Humans, Limbic Encephalitis, Consensus
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: LATE to the PART-y. https://app.cochat.ai/papers/10.1093/brain/awz224
- The paper
- Josephs, K. A., Mackenzie, I., Frosch, M. P., Bigio, E. H., Neumann, M., Arai, T., Dugger, B. N., Ghetti, B., Grossman, M., Hasegawa, M., Herrup, K., Holton, J., Jellinger, K., Lashley, T., McAleese, K. E., Parisi, J. E., Revesz, T., Saito, Y., Vonsattel, J. P., . . . Hu, W. (2019). LATE to the PART-y. Brain. https://doi.org/10.1093/brain/awz224
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.